Immunomodulatory effects of interferon-β-1b in vivo: Induction of the expression of transforming growth factor-β1 and its receptor type II

Journal of Neuroimmunology

Volumn 91, Issue 1-2, 1998, Pages 73-81

  Ossege, L M ^a   Sindern, E ^a   Patzold, T ^a   Malin, J P ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Interferon beta 1b; Lymphocyte subsets; Multiple sclerosis; Soluble vascular adhesion molecule 1; Transforming growth factor beta 1; Tumor necrosis factor receptor (55 kDa)

Indexed keywords

INTERFERON BETA SERINE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTIGENS, CD19; ANTIGENS, CD45; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, COMPLEMENTARY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; LYMPHOCYTE SUBSETS; MALE; MULTIPLE SCLEROSIS; NEUROIMMUNOMODULATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0032476572     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00154-4     Document Type: Article

References (61)

1. Abu Kahbar K.S., Armstrong J.A., Ho M. Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J. Leukocyte Biol. 52:1992;165-172.
2. Antel J.P., Arnason B.G.W., Medorf M.E. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann. Neurol. 5:1979;338-342.
3. Antel J.P., Bania M.B., Reder A., Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 137:1985;137-141.
4. Arnason B.G.W., Antel J.P. Suppressor cell function in multiple sclerosis. Ann. Immunol. Paris. 129C:1978;159-170.
5. Balkwill F.R. Interferons. Lancet. 1:1989;1060-1063.
6. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. New Engl. J. Med. 334:1996;1717-1725.
7. Beutler B., Cerami A. Tumor necrosis, cachexia, shock and inflammation: a common mediator. Annu. Rev. Biochem. 57:1988;505-518.
8. Brod S.A., Marshall G.D. Jr., Henninger E.M., Sriram S., Khan M., Wolinsky J.S. Interferon-β-1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production. Neurology. 46:1996;1633-1638.
9. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L.A., Maloni H., Bash C.N., Frank J.A., McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated in interferon-β-1b. Ann. Neurol. 41:1997;669-674.
10. Calabresi P.A., Peltey C.M., Tranquill L.R., Matoni H., McFarland H.F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon-beta. Neurology. 49:1997;1111-1116.
11. Chen R.H., Moses H.L., Maruoka E.M., Derynck R., Kawabata M. Phosphorylation-dependent interaction of the cytoplasmic domain of the type I and type II transforming growth factor-β receptors. J. Biol. Chem. 270:1995;12235-12241.
12. De Luca G., Lugaresi A., Iarlori C., Marzoli F., Uncini A., Gambi D. Interferon-beta normalizes suppressor cell function in dysimmune neuropathies. J. Neuroimmunol. 82:1998;1-4.
13. Denhardt D.T. A membrane filter technique for detection of complementary DNA. Biochem. Biophys. Res. Commun. 23:1966;641-646.
14. Dore-Duffy P., Newman W., Balabanov R., Lisak R.P., Mainolfi E., Rothlein R., Peterson M. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with disease activity. Ann. Neurol. 37:1995;55-62.
15. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:1983;6-13.
16. Hartung H.P. Pathogenesis of inflammatory demyelination: implications for therapy. Current Opinion in Neurology. 8:1995;191-199.
17. Hartung H.P., Reiners K., Archelos J.J., Michels M., Seeldrayers P., Heidenraich F., Pflughaupt K.W., Toyka K.V. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:1995;186-193.
18. Himmler A., Maurer-Fogy I., Scheurich P., Pfizenmaier K., Lantz M., Olsson I., Hauptmann R., Stratowa C., Adolf G.R. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol. 9:1990;705-715.
19. Jung S., Schluesener H.J., Schmidt B., Fontana A., Toyka K.V. Therapeutic effect of transforming growth factor-β2 on actively induced EAN but not adoptive transfer EAN. Neurology. 83:1994;545-551.
20. Kekow J., Gross W.L. Transforming growth factor-beta: wirkungsweise und klinische bedeutung. Dtsch. Med. Wochenschr. 117:1992;228-235.
21. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
22. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T-cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
23. Lin H.Y., Wang X.F., Ng-Eaton E., Weinberg R.A., Lodish H.F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell. 68:1992;775-785.
24. Link J., Fredrikson S., Söderström M., Olsson T., Höjeberg B., Ljungdahl A., Link H. Organ-specific autoantigens induce transforming growth factor-β mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann. Neurol. 35:1994;197-203.
25. Link J., Söderström M., Olsson T., Höjeberg B., Ljingdahl A., Link H. Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann. Neurol. 36:1994;379-386.
26. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
27. Massague J. Subunit structure of a high-affinity receptor for type beta-transforming growth factor: evidence for a disulfide-linked glycosylated receptor complex. J. Biol. Chem. 260:1985;7059-7066.
28. Matsuda M., Tsukada N., Koichi M., Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T-lymphotropic virus type-1-associated myelopathy. J. Neuroimmunol. 59:1995;35-40.
29. McFarlin D.E., McFarland H.F. Multiple sclerosis. New Engl. J. Med. 307:1982;1183-1188.
30. Miller A., Lider O., Roberts A.B., Sporn M.B., Weiner H.L. Suppressor T-cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor-β after antigen-specific triggering. Proc. Natl. Acad. Sci. USA. 89:1992;421-425.
31. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1993;1548-1561.
32. Noronha A., Toscas A., Jensen M.A. Interferon beta decreases T-cell activation and interferon gamma production in multiple sclerosis. J. Neuroimmunol. 46:1993;1605-1621.
33. Noronha A., Jensen M., Toscas A. TGF-β activity in MS: effect of IFN-β Neurology. 43:1993;355. (suppl.).
34. Ogden, R.C., Adams, D., 1987. Electrophoresis in agarose and acrylamide gels. In: Berger, S.L., Kimmel, A.R. (Eds.), Guide to Molecular Cloning Technique: Methods in Enzymology, Vol. 152. Academic Press, Orlando, pp. 61-87.
35. Olsson T. Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis. Eur. J. Neurol. 1:1994;7-19.
36. Ossege L.M., Voss B., Wiethege T., Sindern E., Malin J.P. Detection of transforming growth factor-beta-1 mRNA in cerebrospinal fluid cells in patients with meningitis by non-radioactive in situ hybridization. J. Neurol. 242:1994;14-19.
37. Ossege L.M., Sindern E., Voss B., Malin J.P. Corticosteroids induce expression of transforming growth factor-beta-1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis. J. Neuroimmunol. 84:1998;1-6.
38. The UBC MS/MRI Study Group, IFNβ MS Study Group, Paty D.W., Li D.K.B. Interferon-β-1b is effective in relapsing and remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind placebo controlled trail. Neurology. 43:1993;662-667.
39. Pette M., Pette D.W., Muraro P.A., Farnon E., Martin R., McFarland H.F. Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology. 49:1997;385-392.
40. Pigott R., Dillon L.P., Hemingway I.H., Gearing A.J.H. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine-activated cultured endothelial cells. Biochem. Biophys. Res. Commun. 187:1992;584-589.
41. Pitzalis C., Sharrack B., Gray I.A., Lee A., Hughes R.A.C. Comparison of the effects of oral vs. intravenous methylprednisolone regimens on peripheral blood T-lymphocyte adhesion molecule expression, T-cell subsets distribution and TNF-alpha concentrations in multiple sclerosis. J. Neuroimmunol. 74:1997;62-68.
42. Porrini A.M., Gambi D., Reder A.T. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis. J. Neuroimmunol. 61:1995;27-34.
43. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K P., Sibley A.W., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
44. Raine C.S. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann. Neurol. 36:1994;S61-S72.
45. Rep M.H.G., Hintzen R.Q., Polman C.H., van Lier R.A.W. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67:1996;11-118.
46. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Brooks A., Lüer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
47. Robert A.B., Sporn M.B. Transforming growth factor-beta. Adv. Cancer Res. 51:1988;107-145.
48. Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A.B., Sporn M.B., Burlington D.B. Effects of transforming growth factor-beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136:1986;3916-3920.
49. Rudick R.A., Ransohoff R.M. Cytokine secretion by multiple sclerosis monocytes: relationship to disease activity. Arch. Neurol. 49:1992;265-270.
50. Satoh J.I., Paty D.W., Kim S.U. Differential effects of beta- and gamma-interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology. 45:1995;367-373.
51. Selmaj K.W., Papierz W., Glabinski A., Kohono T. Prevention of chronic relapsing experimental autoimmune encephalitis by soluble tumor necrosis factor-receptor I. J. Neuroimmunol. 56:1995;135-141.
52. Shalaby M.R., Ammann A.J. Suppression of immune cell function in vitro by recombinant human transforming growth factor-beta. Cell. Immunol. 112:1988;343-350.
53. Sindern E., Schweppe K., Ossege L.M., Malin J.P. Potential role of transforming growth factor-β1 in terminating the immune response in patients with Guillain-Barré syndrome. J. Neurol. 243:1996;264-268.
54. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
55. Stoll G., Jung S., Jander S., van der Meide P., Hartung H.P. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J. Neuroimmunol. 45:1993;175-182.
56. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon-β-1b decreases the migration of T-lymphocytes in vitro: effects in matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
57. Sugarman B.J., Lewis G.D., Essalu T.E., Aggarwal B.B., Shepard H.M. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 37:1987;780-786.
58. The Interferon β Multiple Sclerosis Study Group Clinical results of a multicenter, randomized, double-blind placebo controlled trail. Neurology. 43:1993;655-661.
59. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 334:1988;260-262.
60. Van Zee K., Kohno T., Fischer E., Rock C.S., Moldawer L.L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;4845-4849.
61. Wakefield L.M., Smith D.M., Masui T., Harris C.C., Sporn M.B. Distribution and modulation of the cellular receptor for transforming growth factor-beta. J. Cell Biol. 105:1987;965-975.